AR and prostate carcinoma: Previous studies have demonstrated that BRD4 can promote the transcriptional activities of oncogenic factors in prostate cancer by physically interacting with the N‐terminal domain of androgen receptor (AR), which is a crucial element of the AR signaling pathway.